• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白激酶N1促进肝癌的增殖和侵袭。

Protein kinase N1 promotes proliferation and invasion of liver cancer.

作者信息

Wang Xia, Ge Yansong, Shi Mingqi, Dai Hanhan, Liu Wei, Wang Peiyuan

机构信息

Department of Pathology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China.

Department of Radiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China.

出版信息

Exp Ther Med. 2021 Jun;21(6):651. doi: 10.3892/etm.2021.10083. Epub 2021 Apr 19.

DOI:10.3892/etm.2021.10083
PMID:33968181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8097187/
Abstract

Protein kinase (PK) N1, also called PKC-related protein 1, participates in the proliferation, invasion and metastasis of various malignant tumors. However, the role of PKN1 in liver cancer remains to be elucidated. The present study investigated the expression of PKN1 using immunohistochemistry in surgical specimens from 36 patients and analyzed the correlation with VEGF, microvascular density (MVD), cell proliferation index (Ki67) and clinicopathological parameters. PKN1 was highly expressed in hepatocellular carcinoma (HCC) and was positively correlated with histological grading of HCC, Ki67 expression and MVD. PKN1 expression in moderately and poorly differentiated HCC was significantly higher compared with highly differentiated HCC. Expression of PKN1 was positively correlated with Ki67 and MVD, and Ki67 expression was positively correlated with MVD. The effects of PKN1 on proliferation, invasion and apoptosis of liver cancer cells were detected . Cell viability, migration and invasion were reduced and the apoptosis rate was significantly improved when PKN1 expression was silenced in liver cancer cells. Thus, PKN1 serves an important role in the development and progression of liver cancer. Inhibition of PKN1 activity may provide a promising therapeutic target for liver cancer.

摘要

蛋白激酶(PK)N1,也称为蛋白激酶C相关蛋白1,参与多种恶性肿瘤的增殖、侵袭和转移。然而,PKN1在肝癌中的作用仍有待阐明。本研究采用免疫组织化学方法检测了36例手术标本中PKN1的表达,并分析了其与血管内皮生长因子(VEGF)、微血管密度(MVD)、细胞增殖指数(Ki67)及临床病理参数的相关性。PKN1在肝细胞癌(HCC)中高表达,且与HCC的组织学分级、Ki67表达及MVD呈正相关。中低分化HCC中PKN1的表达明显高于高分化HCC。PKN1的表达与Ki67和MVD呈正相关,且Ki67表达与MVD呈正相关。检测了PKN1对肝癌细胞增殖、侵袭和凋亡的影响。当肝癌细胞中PKN1表达沉默时,细胞活力、迁移和侵袭能力降低,凋亡率显著提高。因此,PKN1在肝癌的发生发展中起重要作用。抑制PKN1活性可能为肝癌提供一个有前景的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/cccc03db89f2/etm-21-06-10083-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/a6bae171a07b/etm-21-06-10083-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/6cb78090adac/etm-21-06-10083-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/63caf798e40e/etm-21-06-10083-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/e9b1cb00129a/etm-21-06-10083-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/cccc03db89f2/etm-21-06-10083-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/a6bae171a07b/etm-21-06-10083-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/6cb78090adac/etm-21-06-10083-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/63caf798e40e/etm-21-06-10083-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/e9b1cb00129a/etm-21-06-10083-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b473/8097187/cccc03db89f2/etm-21-06-10083-g04.jpg

相似文献

1
Protein kinase N1 promotes proliferation and invasion of liver cancer.蛋白激酶N1促进肝癌的增殖和侵袭。
Exp Ther Med. 2021 Jun;21(6):651. doi: 10.3892/etm.2021.10083. Epub 2021 Apr 19.
2
The role of PKN1 in glioma pathogenesis and the antiglioma effect of raloxifene targeting PKN1.PKN1 在神经胶质瘤发病机制中的作用及雷洛昔芬靶向 PKN1 的抗神经胶质瘤作用。
J Cell Mol Med. 2023 Sep;27(18):2730-2743. doi: 10.1111/jcmm.17860. Epub 2023 Jul 21.
3
Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.人肝细胞癌中血管内皮生长因子、微血管密度的定量分析及其临床病理特征
Hepatobiliary Pancreat Dis Int. 2005 May;4(2):220-6.
4
Protein kinase N1 deficiency results in upregulation of cerebral energy metabolism and is highly protective in in vivo and in vitro stroke models.蛋白激酶 N1 缺乏导致脑能量代谢上调,并在体内和体外中风模型中具有高度保护作用。
Metabolism. 2024 Dec;161:156039. doi: 10.1016/j.metabol.2024.156039. Epub 2024 Sep 26.
5
[Relationship between the proliferative activity of cancer cells and microvessel density in portal vein thrombosis and transfer of hepatocellular carcinoma].门静脉癌栓中癌细胞增殖活性与微血管密度及肝细胞癌转移的关系
Zhonghua Gan Zang Bing Za Zhi. 2002 Oct;10(5):366-9.
6
PKN1 modulates TGFβ and EGF signaling in HEC-1-A endometrial cancer cell line.PKN1 调节 HEC-1-A 子宫内膜癌细胞系中的 TGFβ 和 EGF 信号通路。
Onco Targets Ther. 2014 Aug 4;7:1397-408. doi: 10.2147/OTT.S65051. eCollection 2014.
7
Long non-coding RNA CRNDE promotes the proliferation, migration and invasion of hepatocellular carcinoma cells through miR-217/MAPK1 axis.长链非编码 RNA CRNDE 通过 miR-217/MAPK1 轴促进肝癌细胞的增殖、迁移和侵袭。
J Cell Mol Med. 2018 Dec;22(12):5862-5876. doi: 10.1111/jcmm.13856. Epub 2018 Sep 24.
8
Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study.TRAF6与肝癌恶化的关系:一项免疫组织化学和体外研究。
Cancer Cell Int. 2016 Sep 29;16:76. doi: 10.1186/s12935-016-0352-z. eCollection 2016.
9
Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.通过肝动脉灌注利用小干扰RNA沉默血管内皮生长因子对人肝细胞癌肿瘤血管生成的抑制作用
Eur Rev Med Pharmacol Sci. 2015 Dec;19(24):4751-61.
10
RhoA promotes epidermal stem cell proliferation via PKN1-cyclin D1 signaling.RhoA通过PKN1-细胞周期蛋白D1信号通路促进表皮干细胞增殖。
PLoS One. 2017 Feb 21;12(2):e0172613. doi: 10.1371/journal.pone.0172613. eCollection 2017.

引用本文的文献

1
Target Mapping in Cancer: Ligandable Protein Pockets on 3D OncoPPI Networks.癌症中的靶点映射:3D肿瘤蛋白质-蛋白质相互作用网络上的可配体结合蛋白口袋
Pharmaceuticals (Basel). 2025 Jun 25;18(7):958. doi: 10.3390/ph18070958.
2
Novel Flavonoid Derivatives Show Potent Efficacy in Human Lymphoma Models.新型黄酮类衍生物在人类淋巴瘤模型中显示出强大疗效。
EJHaem. 2025 Jun 19;6(3):e70081. doi: 10.1002/jha2.70081. eCollection 2025 Jun.
3
The role of PKN1 in glioma pathogenesis and the antiglioma effect of raloxifene targeting PKN1.PKN1 在神经胶质瘤发病机制中的作用及雷洛昔芬靶向 PKN1 的抗神经胶质瘤作用。

本文引用的文献

1
Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere.肝细胞癌的全身治疗:中国及其他地区的治疗标准
Lancet Oncol. 2020 Apr;21(4):479-481. doi: 10.1016/S1470-2045(20)30082-6. Epub 2020 Feb 26.
2
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.Janus 激酶抑制剂:癌症和自身免疫性疾病的治疗策略。
J Cell Physiol. 2020 Sep;235(9):5903-5924. doi: 10.1002/jcp.29593. Epub 2020 Feb 18.
3
Ramucirumab: A Review in Hepatocellular Carcinoma.雷莫芦单抗:治疗肝细胞癌的研究进展。
J Cell Mol Med. 2023 Sep;27(18):2730-2743. doi: 10.1111/jcmm.17860. Epub 2023 Jul 21.
4
VEGF promotes diabetic retinopathy by upregulating the PKC/ET/NF-κB/ICAM-1 signaling pathway.VEGF 通过上调 PKC/ET/NF-κB/ICAM-1 信号通路促进糖尿病视网膜病变。
Eur J Histochem. 2022 Oct 27;66(4):3522. doi: 10.4081/ejh.2022.3522.
5
Upregulation of PKN1 as a Prognosis Biomarker for Endometrial Cancer.PKN1 上调作为子宫内膜癌的预后生物标志物。
Cancer Control. 2022 Jan-Dec;29:10732748221094797. doi: 10.1177/10732748221094797.
Drugs. 2020 Feb;80(3):315-322. doi: 10.1007/s40265-020-01263-6.
4
Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World.程序性细胞死亡蛋白1(PD-1)靶向免疫疗法在真实世界中治疗晚期肝细胞癌的应用
Onco Targets Ther. 2020 Jan 8;13:143-149. doi: 10.2147/OTT.S234868. eCollection 2020.
5
Cyclin-dependent kinase 1-mediated phosphorylation of protein kinase N1 promotes anchorage-independent growth and migration.周期蛋白依赖性激酶 1 介导的蛋白激酶 N1 磷酸化促进了非锚定依赖性生长和迁移。
Cell Signal. 2020 May;69:109546. doi: 10.1016/j.cellsig.2020.109546. Epub 2020 Jan 22.
6
Molecular therapies for HCC: Looking outside the box.肝细胞癌的分子疗法:跳出框框思考。
J Hepatol. 2020 Feb;72(2):342-352. doi: 10.1016/j.jhep.2019.09.010.
7
[Multimodal treatment of hepatocellular carcinoma].[肝细胞癌的多模式治疗]
Internist (Berl). 2020 Feb;61(2):164-169. doi: 10.1007/s00108-019-00722-x.
8
MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.考比替尼抑制 MEK 可抑制肝癌细胞和血管生成的体内外研究。
Biochem Biophys Res Commun. 2020 Feb 26;523(1):147-152. doi: 10.1016/j.bbrc.2019.12.032. Epub 2019 Dec 11.
9
Histology of Hepatocellular Carcinoma: Association with Clinical Features, Radiological Findings, and Locoregional Therapy Outcomes.肝细胞癌的组织学:与临床特征、影像学表现及局部区域治疗结果的关联
J Clin Imaging Sci. 2019 Nov 18;9:52. doi: 10.25259/JCIS_111_2019. eCollection 2019.
10
Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC).微血管密度(MVD)特征和血管生成抑制剂在肝细胞癌(HCC)治疗方法中的作用。
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):10139-10150. doi: 10.26355/eurrev_201911_19584.